News

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...
(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...
Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Pfizer (PFE-1.64%) and BioNTech (BNTX-1.15%) together pulled off one of the greatest accomplishments in medical history by developing a safe and highly effective COVID-19 vaccine in only a matter ...
Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...